back

Ramucirumab

Subject:

  • Active Substance: Ramucirumab
  • Name: Cyramza®
  • Therapeutic area: Gastric or gastro-oesophageal junction adenocarcinoma
  • Pharmaceutical company: Lilly Deutschland GmbH

 

Time table:

  • Publication of final assessment: 20.03.2015

 

Assessment information:

  • Title: Ramucirumab in combination with Paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction adenocarcinoma
  • Author/Co-Author: NIPHNO (Norway), AAZ (Croatia)
  • Dedicated Reviewers: MoH Slovak Republic (Slovakia), FIMEA (Finland), GYMSZI (Hungary), UCSC Gemelli (Italy), HAS (France)

› G-BA assessment available (D-224)